178 related articles for article (PubMed ID: 26826279)
1. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.
Maina T; Konijnenberg MW; KolencPeitl P; Garnuszek P; Nock BA; Kaloudi A; Kroselj M; Zaletel K; Maecke H; Mansi R; Erba P; von Guggenberg E; Hubalewska-Dydejczyk A; Mikolajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Aug; 91():236-42. PubMed ID: 27185299
[TBL] [Abstract][Full Text] [Related]
3. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
4. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
5. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
6. [
Lezaic L; Erba PA; Decristoforo C; Zaletel K; Mikolajczak R; Maecke H; Maina T; Konijnenberg M; Kolenc P; Trofimiuk-Müldner M; Przybylik-Mazurek E; Virgolini I; de Jong M; Fröberg AC; Rangger C; Di Santo G; Skorkiewicz K; Garnuszek P; Solnica B; Nock BA; Fedak D; Gaweda P; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):892-907. PubMed ID: 36334104
[TBL] [Abstract][Full Text] [Related]
7. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.
Lipiński PFJ; Garnuszek P; Maurin M; Stoll R; Metzler-Nolte N; Wodyński A; Dobrowolski JC; Dudek MK; Orzełowska M; Mikołajczak R
EJNMMI Res; 2018 Apr; 8(1):33. PubMed ID: 29663167
[TBL] [Abstract][Full Text] [Related]
8. Oxidant and Antioxidant Effects of Gentisic Acid in a
Trindade V; Balter H
Curr Radiopharm; 2020; 13(2):107-119. PubMed ID: 31526356
[TBL] [Abstract][Full Text] [Related]
9. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
10. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
11. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
12. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
[TBL] [Abstract][Full Text] [Related]
13. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
14. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.
Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
Cancer Biother Radiopharm; 2016 Feb; 31(1):20-8. PubMed ID: 26844849
[TBL] [Abstract][Full Text] [Related]
15. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
16. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.
Béhé M; Kluge G; Becker W; Gotthardt M; Behr TM
J Nucl Med; 2005 Jun; 46(6):1012-5. PubMed ID: 15937313
[TBL] [Abstract][Full Text] [Related]
17. Kit for preparation of multimeric receptor-specific ⁹⁹mTc-radiopharmaceuticals based on gold nanoparticles.
Ocampo-García B; Ferro-Flores G; Morales-Avila E; Ramírez Fde M
Nucl Med Commun; 2011 Nov; 32(11):1095-104. PubMed ID: 21860334
[TBL] [Abstract][Full Text] [Related]
18. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC.
de Blois E; Chan HS; Konijnenberg M; de Zanger R; Breeman WA
Curr Top Med Chem; 2012; 12(23):2677-85. PubMed ID: 23339763
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
